

Eve Maubec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7975041/publications.pdf>

Version: 2024-02-01

102
papers

5,038
citations

101384

36
h-index

95083

68
g-index

119
all docs

119
docs citations

119
times ranked

7871
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Advanced in the Treatment of Advanced SCC Tumors. <i>Cancers</i> , 2022, 14, 550.	1.7	1
2	Clinical, histopathological and prognostic features of primary cutaneous acral ⁺ Tâ€cell lymphoma and other dermal ⁺ cutaneous lymphoproliferations: results of an ⁺ EORTC</sup> Cutaneous Lymphoma Group workshop*. <i>British Journal of Dermatology</i> , 2022, 186, 887-897.	1.4	12
3	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. <i>British Journal of Dermatology</i> , 2021, 184, 1059-1067.	1.4	39
4	Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 1446.	1.7	12
5	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort dataâ†. <i>Annals of Oncology</i> , 2021, 32, 542-551.	0.6	13
6	The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2243.	1.7	2
7	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. <i>Cancers</i> , 2021, 13, 3547.	1.7	31
8	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. <i>ESMO Open</i> , 2021, 6, 100284.	2.0	7
9	Qualityâ€ofâ€life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	2.0	12
10	Polyomavirus-Positive Merkel Cell Carcinoma Derived from a Trichoblastoma Suggests an Epithelial Origin of this Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 976-985.	0.3	32
11	Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3051-3061.	0.8	106
12	COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice. <i>Journal of Dermatological Treatment</i> , 2020, , 1-2.	1.1	3
13	BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. , 2020, 8, e000275.		11
14	Paraneoplastic neutrophilic leukaemoid reaction in a patient with melanoma: association between tumour volume and leucocytosis. <i>British Journal of Dermatology</i> , 2020, 183, 579-580.	1.4	4
15	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	1.7	17
16	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 931.	1.7	12
17	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	0.6	29
18	Update of the Management of Cutaneous Squamous-cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00143.	0.6	35

#	ARTICLE	IF	CITATIONS
19	Machine learning models to predict the response to anti-cancer therapy in metastatic melanoma patients.. Journal of Clinical Oncology, 2020, 38, e14071-e14071.	0.8	4
20	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy, 2019, 11, 1005-1013.	1.0	21
21	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. JAMA Dermatology, 2019, 155, 673.	2.0	7
22	Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Frontiers in Medicine, 2019, 6, 249.	1.2	18
23	Primary cutaneous acral ⁸ Tâ€cell lymphomas relapse more frequently in younger patients. British Journal of Haematology, 2019, 185, 598-601.	1.2	7
24	Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.. Journal of Clinical Oncology, 2019, 37, 9547-9547.	0.8	18
25	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, LegâType. Journal of Investigative Dermatology, 2018, 138, 1982-1989.	0.3	27
26	Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. Journal of Oncology, 2018, 2018, 1-9.	0.6	53
27	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. Frontiers in Medicine, 2018, 5, 268.	1.2	49
28	Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.. Journal of Clinical Oncology, 2018, 36, 9534-9534.	0.8	19
29	Carcinome Ã©pidermoÃ©de cutanÃ© : actualitÃ©s sur la physiopathologie et les stratÃ©gies thÃ©rapeutiques. Oncologie, 2018, 20, 33-36.	0.2	1
30	Epidemiological study of unknown primary melanoma patients from the French national melanoma database RIC-Mel.. Journal of Clinical Oncology, 2018, 36, e21571-e21571.	0.8	2
31	Metformin monotherapy in melanoma: a pilot, openâ€label, prospective, and multicentric study indicates no benefit. Pigment Cell and Melanoma Research, 2017, 30, 378-380.	1.5	23
32	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nature Communications, 2017, 8, 15034.	5.8	40
33	Estimation of The Cost of Metastatic Melanoma in France Using Melbase Data. Value in Health, 2017, 20, A427-A428.	0.1	0
34	CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology, 2017, 35, TPS9596-TPS9596.	0.8	3
35	Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase.. Journal of Clinical Oncology, 2017, 35, 9551-9551.	0.8	0
36	Micro- and macro-metastatic disease kinetics: Results from the French cohort Melbase.. Journal of Clinical Oncology, 2017, 35, 9538-9538.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients. <i>Annals of Oncology</i> , 2016, 27, vi391.	0.6	0
38	Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2016, 174, 813-822.	1.4	56
39	Effectiveness and Safety of Vemurafenib as Monotherapy in Unresectable or Metastatic Melanoma from an Academic Database: Real World Data to Strengthen Evidence for Payer. <i>Value in Health</i> , 2016, 19, A762-A763.	0.1	0
40	First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. <i>British Journal of Cancer</i> , 2016, 114, 1199-1205.	2.9	30
41	Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapy. <i>Annals of Oncology</i> , 2016, 27, 914-919.	0.6	63
42	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. <i>International Immunopharmacology</i> , 2016, 40, 466-473.	1.7	25
43	Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. <i>British Journal of Dermatology</i> , 2016, 174, 56-67.	1.4	102
44	A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between <i>CDC42</i> and <i>SCIN</i> genetic variants. <i>International Journal of Cancer</i> , 2016, 139, 2012-2020.	2.3	8
45	Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2080-2089.	0.3	31
46	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>OncImmunology</i> , 2016, 5, 1136045.	2.1	22
47	Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. <i>Targeted Oncology</i> , 2016, 11, 59-69.	1.7	43
48	Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9556-9556.	0.8	2
49	Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSÂ© Program.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS11620-TPS11620.	0.8	1
50	Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at <i>TERF1</i> and <i>AFAP1L2</i> loci on melanoma risk. <i>International Journal of Cancer</i> , 2015, 137, 1901-1909.	2.3	16
51	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. <i>British Journal of Dermatology</i> , 2015, 173, 1015-1023.	1.4	11
52	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0133363.	1.1	14
53	SÂ©zary syndrome without erythroderma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1003-1009.e1.	0.6	19
54	Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1781-1789.	0.3	40

#	ARTICLE	IF	CITATIONS
55	First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.. Journal of Clinical Oncology, 2015, 33, 2555-2555.	0.8	0
56	Mature Cytotoxic CD56 ^{bright} /CD16 ⁺ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. Cancer Research, 2014, 74, 81-92.	0.4	85
57	Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumors. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2014, 131, 375-383.	0.4	16
58	Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 298-308.	1.3	24
59	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. JAMA Dermatology, 2014, 150, 535.	2.0	80
60	French ENT Society (SFORL) guidelines for the management of immunodeficient patients with head and neck cancer of cutaneous origin. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2014, 131, 121-129.	0.4	10
61	Therapy of Advanced Squamous Cell Carcinoma of the Skin. Current Treatment Options in Oncology, 2014, 15, 302-320.	1.3	28
62	Sentinel node biopsy in the initial evaluation of 87 patients with Merkel cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 9015-9015.	0.8	2
63	Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma?. Journal of Clinical Oncology, 2014, 32, 9092-9092.	0.8	4
64	Virus et cancerogenèse cutanée. , 2014, , 285-289.		0
65	Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families. British Journal of Dermatology, 2013, 169, 594-599.	1.4	15
66	Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. British Journal of Dermatology, 2013, 169, 579-586.	1.4	141
67	Clinical Activity of Lenalidomide in Visceral Human Immunodeficiency Virus-Related Kaposi Sarcoma. JAMA Dermatology, 2013, 149, 1319.	2.0	13
68	Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages. PLoS ONE, 2013, 8, e76928.	1.1	58
69	Familial melanoma: Clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. Journal of the American Academy of Dermatology, 2012, 67, 1257-1264.e2.	0.6	26
70	Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Human Molecular Genetics, 2011, 20, 5012-5023.	1.4	187
71	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	9.4	230
72	Pregnancy Promotes Melanoma Metastasis through Enhanced Lymphangiogenesis. American Journal of Pathology, 2011, 178, 1870-1880.	1.9	40

#	ARTICLE	IF	CITATIONS
73	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. <i>Nature</i> , 2011, 480, 94-98.	13.7	466
74	Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors. <i>PLoS ONE</i> , 2011, 6, e17621.	1.1	81
75	Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunosuppression. <i>PLoS ONE</i> , 2011, 6, e29451.	1.1	18
76	Sentinel Lymph Node Biopsy or Nodal Observation in Melanoma: A Prospective Study of Patient Choices. <i>Dermatologic Surgery</i> , 2011, 37, 199-206.	0.4	7
77	Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1300-1307.	0.3	72
78	Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. <i>Journal of Clinical Oncology</i> , 2011, 29, 3419-3426.	0.8	387
79	High Levels of Antibodies Against Merkel Cell Polyomavirus Identify a Subset of Patients With Merkel Cell Carcinoma With Better Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1612-1619.	0.8	151
80	Characteristics of the coexistence of melanoma and renal cell carcinoma. <i>Cancer</i> , 2010, 116, 5716-5724.	2.0	22
81	The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. <i>Experimental Dermatology</i> , 2010, 19, 100-107.	1.4	46
82	Management and outcome of metastatic melanoma during pregnancy. <i>British Journal of Dermatology</i> , 2010, 162, 274-281.	1.4	60
83	Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?. <i>British Journal of Dermatology</i> , 2010, 162, 74-79.	1.4	136
84	Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3288-3295.	3.2	128
85	Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1568-1583.	3.0	108
86	Distinct Merkel Cell Polyomavirus Molecular Features in Tumour and Non Tumour Specimens from Patients with Merkel Cell Carcinoma. <i>PLoS Pathogens</i> , 2010, 6, e1001076.	2.1	119
87	Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab. <i>Archives of Dermatology</i> , 2009, 145, 329-30.	1.7	37
88	Fetal Microchimeric Cells Participate in Tumour Angiogenesis in Melanomas Occurring during Pregnancy. <i>American Journal of Pathology</i> , 2009, 174, 630-637.	1.9	77
89	The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. <i>British Journal of Cancer</i> , 2008, 99, 364-370.	2.9	25
90	Minocycline-Induced DRESS: Evidence for Accumulation of the Culprit Drug. <i>Dermatology</i> , 2008, 216, 200-204.	0.9	48

#	ARTICLE	IF	CITATIONS
91	Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin: Preliminary results of a phase II multicenter study. <i>Journal of Clinical Oncology</i> , 2008, 26, 9042-9042.	0.8	3
92	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Archives of Dermatology</i> , 2007, 143, 1144-50.	1.7	218
93	F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4mm. <i>Melanoma Research</i> , 2007, 17, 147-154.	0.6	51
94	Indolent CD8-positive Lymphoid Proliferation of the Ear. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1887-1892.	2.1	175
95	Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia. <i>American Journal of Pathology</i> , 2007, 171, 846-860.	1.9	69
96	Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 070209222700006-???	1.3	27
97	Mixed Nonseminomatous Germ Cell Tumor Presenting as a Subcutaneous Tissue Mass. <i>American Journal of Dermatopathology</i> , 2006, 28, 523-525.	0.3	12
98	Common skin cancers in porokeratosis. <i>British Journal of Dermatology</i> , 2005, 152, 1389-1391.	1.4	57
99	Vaccination-induced cutaneous pseudolymphoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 623-629.	0.6	94
100	Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. <i>Anticancer Research</i> , 2005, 25, 1205-10.	0.5	73
101	Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. <i>Cancer Gene Therapy</i> , 2003, 10, 481-490.	2.2	30
102	Immune recovery inflammatory folliculitis. <i>Aids</i> , 2000, 14, 617-618.	1.0	33